Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study-Reference-Cited by-同舟云学术

Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study

Published:2023-06-27 Issue:4 Volume:41 Page:579-586
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Wang Xue,Huang Jinxiang,Huang He,Liu Yang,Ji Chao,Liu Jian

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-023-01379-y.pdf

Reference29 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin 71(3):209–249

2. Pyo JH, Lee H, Min BH, Lee JH, Choi MG, Lee JH et al (2016) Long-term outcome of endoscopic resection vs. surgery for early gastric Cancer: a non-inferiority-matched cohort study. Am J Gastroenterol 111(2):240–249

3. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet (London England) 393(10184):1948–1957

4. Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY et al (2021) PRODIGY: a phase III study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 plus surgery and adjuvant S-1 Versus surgery and adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin oncology: official J Am Soc Clin Oncol 39(26):2903–2913

5. Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z et al (2021) Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol 22(8):1081–1092

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of tumor regression grade in far-advanced gastric cancer after preoperative immuno-chemotherapy using dual-energy CT-derived extracellular volume fraction;European Radiology;2024-07-09

2. Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review;Frontiers in Immunology;2024-01-30

3. Research Progress of Immunotherapy in Neoadjuvant Therapy of Gastric Cancer;Journal of Clinical Personalized Medicine;2024